The achievement of a key milestone by the clinical care team at Stanford Health Care, which has surpassed 100 cases for CellTolerance tests using the Cellvizio platform for patients with suspected food intolerance.

Mauna Kea experiences growing momentum for its CellTolerance application, prompting the company to open new geographic markets with strong growth potential.

The CellTolerance Test powered by Cellvizio® technology, represents a paradigm shift in how physicians diagnose and treat food intolerances.

Mauna Kea Technologies, inventor of Cellvizio®, unveils its new subsidiary CellTolerance, fully dedicated to its unique program for the detection and treatment of food intolerances associated with Irritable Bowel Syndrome (IBS).

Key organizational changes to accelerate the international growth of CellTolerance®. This strategic move focuses on scaling the rapid adoption of real-time food intolerance detection for patients suffering from IBS in markets outside the United States.

Join our CellTolerance Live Cases workshop in Bamberg, Germany on June 22 and learn about the detection of food intolerance with Prof. Jost Langhorst.

Connect with our team at Digestive Disease Week (DDW) 2026 and discover how the CellTolerance test is transforming the management of food-related IBS in patients.

Join us at United European Gastroenterology Week in Copenhagen this October to learn about the latest advances in food sensitivity testing.

Latest research validates the reliability of confocal laser endomicroscopy for detecting food-induced mucosal reactions in IBS patients.

Mauna Kea Technologies announces the expansion of CellTolerance services to Austria, bringing advanced food intolerance testing to Central European patients.